BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GeneLink, Inc. (GNLK) Reports Third Quarter Results


11/18/2010 11:20:48 AM

ORLANDO, Fla., Nov. 18, 2010 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTCBB: GNLK), a leading consumer genomics biotech company, today reported financial results for the fiscal quarter ended September 30, 2010.

Highlights:

  • Gross Profit Margin Increase of 28%
  • GeneLink named to Deloitte's Technology Fast 500 for the second year in a row
  • GeneLink announces Private Label Agreement with Helix Life

Gary Beeman, GeneLink's CEO stated, "The third quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins as margins increased 28% over the comparable quarter -- a significant accomplishment. Our top line sales were down slightly, due in part to seasonality in our GeneWize market sector and the continuing US economic conditions. We were pleased that GeneLink was honored with its second Deloitte's Technology Fast 500 award as the 62nd fastest growing company in North America in 2009, 17th fastest in the Biotechnology/Pharmaceutical sector. We announced our 'Powered by GeneLink' private label DNA technology licensing program with health and wellness products provider HelixLife (www.HelixLife.com) in the third quarter. GeneLink also announced new 'youth' products for our nutritional and skin care lines which will now allow us to serve the important and influential 12-18 year-old market sector, giving us the ability to now serve entire families through our GeneWize direct selling channel and also HelixLife. We expect these and other initiatives to contribute to our top-line growth going forward. The combination of fundamental profit improvement and increasing and diversified revenue opportunities globally is our strategy for shareholder value."

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "I am pleased to see GeneLink focusing on its core competitive strengths again. In the third quarter our Scientific Advisory Board and Management Team has been focused on R&D, product development, infrastructure expansion and continued leadership in regulatory compliance and quality. As the pioneer in genetically-guided nutrition and skin care, GeneLink continues to focus on strengthening our leadership position and leading the growth in consumer genetics."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs. For more information visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES